Exact Sciences Stock (NASDAQ:EXAS)
Previous Close
$101.65
52W Range
$38.81 - $102.66
50D Avg
$88.52
200D Avg
$60.54
Market Cap
$19.26B
Avg Vol (3M)
$5.44M
Beta
1.41
Div Yield
-
EXAS Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 24 | Dec 22 | Dec 21 |
|---|---|---|---|
| Precision Oncology | $655.00M | - | - |
| COVID-19 Testing | - | $58.09M | $143.10M |
| Screening | $2.10B | - | - |
| Product | - | $545.46M | $438.65M |
| Product and Service, Other | - | $136.01M | $53.72M |
| International Sales | - | $117.74M | $109.91M |
| Service | - | $743.24M | $569.94M |
Fiscal year ends in Dec 24 | Currency in USD